Freedom (FRHC) had the highest return between 2017 and 2019 by a mid-cap US stock, returning 10,474.5%.
| ASSET | YEARS | % RETURN |
|---|---|---|
Freedom (FRHC) | 2017-2019 | 10,474.55% |
Arrowhead Pharmaceuticals (ARWR) | 2017-2019 | 3,966.03% |
Enphase Energy (ENPH) | 2017-2019 | 2,461.76% |
Axsome Therapeutics (AXSM) | 2017-2019 | 1,376.57% |
Novocure (NVCR) | 2017-2019 | 960% |
Ringcentral (RNG) | 2017-2019 | 703.19% |
Ascendis Pharma A-S (ASND) | 2017-2019 | 596.64% |
RH (RH) | 2017-2019 | 593.18% |
EXACT Sciences (EXAS) | 2017-2019 | 579.5% |
Viking Therapeutics (VKTX) | 2017-2019 | 568.33% |
Madrigal Pharmaceuticals (MDGL) | 2017-2019 | 509.43% |
Crocs (CROX) | 2017-2019 | 501.87% |
Freshpet (FRPT) | 2017-2019 | 479.31% |
Vericel Corp Ord (VCEL) | 2017-2019 | 470.49% |
GDS (GDS) | 2017-2019 | 464.33% |
PAR Technology (PAR) | 2017-2019 | 449.91% |
Krystal Biotech (KRYS) | 2017-2019 | 427.43% |
Match (MTCH) | 2017-2019 | 400.71% |
Appfolio (APPF) | 2017-2019 | 359.08% |
Five9 (FIVN) | 2017-2019 | 357.64% |
PTC Therapeutics (PTCT) | 2017-2019 | 334.27% |
Leonardo DRS, Inc Common Stock (DRS) | 2017-2019 | 328.93% |
Novanta (NOVT) | 2017-2019 | 316.19% |
TAL Education (TAL) | 2017-2019 | 308.98% |
Amedisys (AMED) | 2017-2019 | 289.54% |
Mid-cap stocks are treated as having a market cap between $2B and $10B.
